Trial reportThe Journal of dermatology2019
Efficacy of long-term treatment with efinaconazole 10% solution in patients with onychomycosis, including severe cases: A multicenter, single-arm study.
Trial report in The Journal of dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Trial
- Treating Onychomycosis with Efinaconazole: Considerations for Diverse Patient Groups.Journal of fungi (Basel, Switzerland) · 2025Review
- Efficacy of Topical Antifungal Nail Solution Versus Topical Placebo Solution for the Treatment of Pedal Onychomycosis: A Randomized Controlled Trial.Infectious diseases and therapy · 2025Article
- New Formulation-Microporation Combination Approaches to Delivering Ciclopirox across Human Nails.Pharmaceutics · 2024Article
- Terbinafine in acrylic polymer for the treatment of onychomycosis in hemodialysis patients: a phase II clinical trial.Frontiers in medicine · 2024Article
- Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes.Infection and drug resistance · 2024Review
- On the Basis of Sex: Impact and Treatment of Toenail Onychomycosis in Female Patients.The Journal of clinical and aesthetic dermatology · 2023Review
- Evaluation of Topical Antifungals Using a New Predictive Animal Model for Efficacy against Severe Tinea Unguium: A Comparison of Efinaconazole and Luliconazole.Mycopathologia · 2022Article
- Dermatophytomas: Clinical Overview and Treatment.Journal of fungi (Basel, Switzerland) · 2022Review
- Ciclopirox Hydroxypropyl Chitosan (CPX-HPCH) Nail Lacquer and Breathable Cosmetic Nail Polish: In Vitro Evaluation of Drug Transungual Permeation Following the Combined Application.Life (Basel, Switzerland) · 2022Article
- Printing Drugs onto Nails for Effective Treatment of Onychomycosis.Pharmaceutics · 2022Article
- Updated Perspectives on the Diagnosis and Management of Onychomycosis.Clinical, cosmetic and investigational dermatology · 2022Review
- Clinical effectiveness of efinaconazole 10% solution for treatment of onychomycosis with longitudinal spikes.The Journal of dermatology · 2021Article
- Topical efinaconazole: A sequential combination therapy with oral terbinafine for refractory tinea unguium.The Journal of dermatology · 2021Article
- Treatment Outcome with Fosravuconazole for Onychomycosis.Mycopathologia · 2021Article
- Ciclopirox and Efinaconazole Transungual Permeation, Antifungal Activity, and Proficiency To Induce Resistance in Trichophyton rubrum.Antimicrobial agents and chemotherapy · 2019Article
- Diagnosis and management of tinea infections.American family physician · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 19 institutions in 1 country.
Funding
Abstract
We evaluated the efficacy of efinaconazole 10% topical solution in long-term use, for up to 72 weeks, for onychomycosis, including severe cases. Among 605 participants, 219 patients diagnosed as having onychomycosis were evaluated for the efficacy of efinaconazole. The treatment success rate (<10% clinical involvement of the target toenail) at the final assessment time point was 56.6%, the complete cure rate was 31.1% and the mycological cure rate was 61.6%, all of which increased over time, demonstrating that continuous application contributed to the improvement of cure rate. Even in severe cases, reduction of the affected nail area was observed, showing the potential efficacy of the treatment. Responses to a quality of life questionnaire among patients with onychomycosis, OnyCOE-t, suggested that efinaconazole treatment improved the patients' quality of life. The incidence of adverse drug reaction in the patients eligible for the assessment was 6.3%, and this developed only in the administration site in all cases. No systemic adverse event was observed. In addition, no increase in the incidence of adverse drug reaction due to long-term use was found. Efinaconazole therapy was proved to exhibit excellent balance between efficacy and safety, and thus may serve as a useful treatment option for onychomycosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.